These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 23100520

  • 1. Time to talk about timing--when to start, stop and change anti-migratory drugs in MS.
    Stüve O, Hemmer B.
    Mult Scler; 2012 Nov; 18(11):1514-6. PubMed ID: 23100520
    [No Abstract] [Full Text] [Related]

  • 2. Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod.
    Jander S, Turowski B, Kieseier BC, Hartung HP.
    Mult Scler; 2012 Nov; 18(11):1650-2. PubMed ID: 23100527
    [Abstract] [Full Text] [Related]

  • 3. Early switch to fingolimod may decrease the risk of disease recurrence after natalizumab interruption.
    Laroni A, Brogi D, Milesi V, Abate L, Uccelli A, Mancardi G.
    Mult Scler; 2013 Aug; 19(9):1236-7. PubMed ID: 23184503
    [No Abstract] [Full Text] [Related]

  • 4. In the coming year we should abandon interferons and glatiramer acetate as first-line therapy for MS: yes.
    Fox RJ.
    Mult Scler; 2013 Jan; 19(1):24-5. PubMed ID: 23303880
    [No Abstract] [Full Text] [Related]

  • 5. Severe multiple sclerosis reactivation under fingolimod 3 months after natalizumab withdrawal.
    Daelman L, Maitrot A, Maarouf A, Chaunu MP, Papeix C, Tourbah A.
    Mult Scler; 2012 Nov; 18(11):1647-9. PubMed ID: 22907938
    [Abstract] [Full Text] [Related]

  • 6. Switching therapy from natalizumab to fingolimod in relapsing-remitting multiple sclerosis: clinical and magnetic resonance imaging findings.
    Rinaldi F, Seppi D, Calabrese M, Perini P, Gallo P.
    Mult Scler; 2012 Nov; 18(11):1640-3. PubMed ID: 23100526
    [Abstract] [Full Text] [Related]

  • 7. Reduction of the washout time between natalizumab and fingolimod.
    de Seze J, Ongagna JC, Collongues N, Zaenker C, Courtois S, Fleury M, Benoilid A, Chanson JB, Blanc F, Alsacep Network.
    Mult Scler; 2013 Aug; 19(9):1248. PubMed ID: 23722322
    [No Abstract] [Full Text] [Related]

  • 8. Withdrawal of fingolimod treatment for relapsing-remitting multiple sclerosis: report of six cases.
    Hakiki B, Portaccio E, Giannini M, Razzolini L, Pastò L, Amato MP.
    Mult Scler; 2012 Nov; 18(11):1636-9. PubMed ID: 22829326
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Moving to fingolimod from natalizumab in multiple sclerosis-reply.
    Cohen M, Lebrun C.
    JAMA Neurol; 2014 Jul 01; 71(7):925. PubMed ID: 25023556
    [No Abstract] [Full Text] [Related]

  • 13. Magnetic resonance imaging as surrogate for clinical endpoints in multiple sclerosis: data on novel oral drugs.
    Sormani MP, Bonzano L, Roccatagliata L, De Stefano N.
    Mult Scler; 2011 May 01; 17(5):630-3. PubMed ID: 21177320
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Oral fingolimod (gilenya) for multiple sclerosis.
    Med Lett Drugs Ther; 2010 Dec 29; 52(1353-1354):98-9. PubMed ID: 21344782
    [No Abstract] [Full Text] [Related]

  • 17. Multiple sclerosis: Natalizumab to fingolimod--the washout whitewash.
    Stangel M, Stüve O.
    Nat Rev Neurol; 2014 Jun 29; 10(6):311-3. PubMed ID: 24840971
    [No Abstract] [Full Text] [Related]

  • 18. Multiple sclerosis therapeutic pipeline: opportunities and challenges.
    Krieger S.
    Mt Sinai J Med; 2011 Jun 29; 78(2):192-206. PubMed ID: 21425264
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.